Guardian Pharmacy Services, Inc.

What they do

Guardian provides technology-enabled pharmacy services to residents of long-term care facilities (LTCFs), primarily assisted living facilities (ALFs) and behavioral health facilities (BHFs). Services include prescription intake, medication packaging, electronic tracking of drug administration, caregiver training, and mock audits. The company enters contracts directly with LTCFs to serve as the principal pharmacy provider for their residents.

Revenue drivers

• ALF and BHF residents — More than two-thirds of annual revenue for each of the past three years came from residents of ALFs and BHFs, the company's target markets.
• Skilled nursing facilities (SNFs) — The remainder of revenue is generated primarily from residents of skilled nursing facilities.

Recent performance

For Q2 2026 (quarter ended June 30, 2026), revenue was $351.8 million, up 2% year-over-year, and net income was $22.1 million, including an $8.5 million settlement related to a payor dispute. Adjusted EBITDA was $29.7 million, up from $25.0 million in the prior-year period. Diluted EPS was $0.34, with Adjusted EPS of $0.29. The company had cash and cash equivalents of $89.8 million and no long-term debt outstanding.

Strategy

Guardian's core growth strategy focuses on increasing the number of residents served through a mix of organic and acquired growth. The company develops greenfield pharmacies and pursues acquisitions, such as the recent Wellness Concepts acquisition in Virginia and a new greenfield pharmacy in Lexington, Kentucky. Management has also implemented a regional leadership structure with eight regional senior vice presidents to strengthen accountability and support local pharmacy teams.

Risks

• Intense competition — The LTC pharmacy market is highly competitive, and larger competitors with more resources may focus more on the ALF market, which could pressure margins.
• Pricing pressure from IRA — IRA-related pricing reductions negatively affected reported revenue growth in Q2 2026, and such pressures could persist.
• Freedom of choice laws — Residents have the right to choose their pharmacy, which can limit the company's ability to retain or grow residents at a facility.
• Resident adoption challenges — Growth depends on increasing resident adoption at existing facilities, which may not always be achieved.

Outlook

For FY 2026, Guardian raised its guidance, now expecting revenue of $1.43 billion to $1.45 billion and Adjusted EBITDA of $129 million to $131 million. The guidance excludes any future acquisitions.